Summary - REGN - NASDAQ - Weiss Ratings

D

Regeneron Pharmaceuticals, Inc. REGN

$490.28 -$115.11-19.01% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

52-Week Range

$520.50 - $1,211.20

P/E (TTM)

EPS (TTM)

My Lists My Alerts

Biotechnology Health Care Pharmaceutical Drugs

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

5/15/2025 - MarketBeat

Regeneron Pharmaceuticals (REGN, $490.28) RSI Indicator left the oversold zone on May 30, 2025

5/31/2025 - Tickeron - Technical Analysis

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

5/30/2025 - Investopedia Headlines

Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals

5/30/2025 - Benzinga

Regeneron Pharmaceuticals (REGN) Faces Rating Downgrade by Wells Fargo REGN Stock News

5/30/2025 - GuruFocus

Top Medical Stocks To Consider - May 30th

5/30/2025 - MarketBeat

Video: Friday's ETF with Unusual Volume: DSTL

5/30/2025 - Market News Video

Video: Nasdaq 100 Movers: REGN, ZS

5/30/2025 - Market News Video

Video: S&P 500 Movers: REGN, ULTA

5/30/2025 - Market News Video

Noteworthy Friday Option Activity: BKNG, REGN, BA

5/30/2025 - Stock Options Channel

Why Regeneron (REGN) Shares Are Falling Today

5/30/2025 - StockStory Articles

Regeneron Pharmaceuticals Unusual Options Activity For May 30

5/30/2025 - Benzinga

Regeneron stock crashes on COPD data: here's why I'm buying REGN today

5/30/2025 - Invezz News

Regeneron shares plunge after mixed COPD drug trial results

5/30/2025 - Proactive Investors - UK

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

5/30/2025 - Investopedia Headlines

COPD Drug Developed by Regeneron, Sanofi Fails Key Test

5/30/2025 - Investopedia Headlines

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

5/30/2025 - Zacks Investment Research

Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies

5/30/2025 - Zacks Investment Research

S&P 500 (NYSEARCA: SPY) Live: Markets Retreat on US-China Trade Jitters

5/30/2025 - 24/7 Wall St.

Live Nasdaq Composite: Fear Grips Markets as China Trade Deal Unravels

5/30/2025 - 24/7 Wall St.

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

5/30/2025 - Benzinga

Boston Common Asset Management LLC Acquires 5,525 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

5/30/2025 - MarketBeat

Jacobs & Co. CA Buys 859 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

5/30/2025 - MarketBeat

RK Asset Management LLC Has $7.97 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

5/30/2025 - MarketBeat

Best Biotech Stocks to Buy in 2025

5/13/2025 - MarketBeat

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Tuesday, April 29, 2025

Period Date

Monday, March 31, 2025

Next Filing

Beginning of August (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

May 08, 2025 - $520.50

52-week High

Aug 27, 2024 - $1,211.20

Valuation

Market Cap

$62.54B - Large Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

Dividend Per Share (TTM)

Corporate Info

Website

www.regeneron.com

Phone Number

914 847 7000

Address

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more